查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1584109

頭孢克松市場，按適應症、配銷通路、國家和地區 - 2024-2032年產業分析、市場規模、市場佔有率和預測

Ceftriaxone Market, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年頭孢克松市場規模為201,032萬美元，2024年至2032年年複合成長率為3.29%。

頭孢克松市場-市場動態

公眾意識的提高以及更容易感染細菌性疾病的老年人口的增加推動了市場需求

頭孢克松經由靜脈或肌肉注射給藥。口服時，其生物利​​用度低於1%。主要用於治療泌尿道感染、腹腔內感染、心內膜炎、急性細菌性中耳炎、腦膜炎、肺炎等。此外，頭孢克松可作為青黴素過敏患者神經梅毒的第一線治療藥物。在某些手術之前也會進行注射，以防止術後感染。頭孢克松的常見副作用包括疼痛、堅硬、壓痛、皮膚蒼白、腹瀉、虛弱和運動時呼吸短促。然而，值得注意的是，頭孢克松對感冒和流感等病毒感染無效。該藥物必須有醫生處方才能使用。由於泌尿道感染（UTI）發病率的增加、公眾意識的提高以及更容易感染細菌性疾病的老年人口的增加，預計全球頭孢克松市場在不久的將來將成長。預計未來幾年全球主要慢性病的盛行率將大幅上升。泌尿道感染、急性細菌性中耳炎、腹內感染和其他細菌性疾病的發生不斷增加，推動了對頭孢克松注射的需求。泌尿道感染通常是由進入膀胱的細菌引起的，在女性中尤其常見，超過一半的人可能一生中至少經歷過一次泌尿道感染。這些感染可能會帶來痛苦並造成嚴重的健康風險。頭孢克松用於治療泌尿道感染的使用的增加預計將有助於頭孢克松市場的擴大。根據國家生物技術資訊中心的資料，大約 80%的兒童在其一生中至少會經歷一次中耳炎，其中 80%至 90%的兒童在達到學齡前可能患有滲出性中耳炎。此外，老年人口的不斷增加，特別是在已開發國家，可能會增加對頭孢克松注射液的需求，因為細菌感染在 65 歲以上的人群中更為普遍。

頭孢克松市場-關鍵見解

根據研究分析師分享的分析，預計全球市場在預測期內（2024-2032年）每年將以 3.29%左右的年複合成長率成長

根據適應症細分，預計肺炎將在2023年呈現最大市場佔有率

從配銷通路細分來看，醫院藥局是2023年的主導類型

依地區分類，北美是2023年的主要收入來源

頭孢克松市場-細分分析：

全球頭孢克松市場根據適應症、配銷通路和地區進行細分。

市場依適應症分為七類：泌尿道感染、腹腔內感染、心內膜炎、急性細菌性中耳炎、腦膜炎、肺炎等。在頭孢克松市場中，肺炎是主要的適應症，這是由於社區獲得性和醫院獲得性肺炎盛行率不斷上升，特別是在老年人和免疫功能低下患者等弱勢群體中。頭孢克松對多種病原體具有廣譜功效，使其成為一線治療藥物，因其在治療重症病例方面的有效性而經常在醫院環境中使用。雖然泌尿道感染和腦膜炎等其他適應症也值得注意，但肺炎的高發生率和對有效治療的迫切需求鞏固了其作為頭孢克松主要適應症的地位。

根據配銷通路，市場分為三類：醫院藥房、零售藥房和網路藥房。在配銷通路領域，醫院藥局在頭孢克松市場中佔據主導地位。這種優點主要是由於藥物主要用於住院治療需要立即就醫的嚴重感染。醫院藥局對於確保需要重症監護的患者及時獲得頭孢克松非常重要。儘管零售和線上藥局對於門診管理非常重要，但醫院環境中對頭孢克松的迫切需求推動了其大部分銷售透過醫院藥局進行，凸顯了其所解決的感染的關鍵性質。

頭孢克松市場-地理洞察

該市場涵蓋北美、歐洲、拉丁美洲、亞太地區、中東和非洲。這些地區的參與國家在市場內創造細分市場。2023年，北美佔據頭孢克松市場的最大佔有率，將其定位為預測期內成長利潤豐厚的地區。這種主導地位可歸因於細菌感染發生率的上升。此外，該地區受益於技術先進產品的高採用率、大量的醫療保健支出、早期獲得創新技術以及政府和慈善組織對醫療保健研究的有利資助。預計這些因素將在未來幾年推動頭孢克松市場的擴張。美國成為北美地區的領導者，很大程度上是由於主要行業參與者的存在。

頭孢克松市場-競爭格局：

頭孢克松市場的公司實施各種策略來保持競爭力並促進成長。進行的研究和開發工作致力於改進配方，例如創建針對抗藥性菌株的緩釋版本或聯合療法。與醫療保健提供者和機構的策略聯盟促進臨床試驗並擴大藥物在各種醫療環境中的應用。行銷活動強調該藥物的功效、安全性和治療常見感染的多功能性，針對處方者和醫院。此外，公司經常參與教育活動，以提高人們對正確使用抗生素的認知，並推廣頭孢克松作為第一線治療藥物，同時解決抗生素抗藥性問題。

最新進展：

2021年9月，印度政府對從中國進口的頭孢克松原料實施反傾銷稅，以保護國內製造商免受低成本進口產品的影響。

目錄

第1章 頭孢克松市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘錄
    • 依適應症分類的頭孢克松市場摘錄
    • 依配銷通路分類的頭孢克松市場摘錄
    • 依國家分類的頭孢克松市場摘錄
    • 依地區分類的頭孢克松市場摘錄
  • 競爭洞察

第3章 頭孢克松主要市場趨勢

  • 頭孢克松市場促進因素
    • 市場促進因素的影響分析
  • 頭孢克松市場限制
    • 市場限制影響分析
  • 頭孢克松的市場機會
  • 頭孢克松市場未來趨勢

第4章 頭孢克松產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 頭孢克松市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 頭孢克松市場格局

  • 2023年頭孢克松市佔分析
  • 依主要製造商分類的細分資料
    • 既有參與者分析
    • 新興參與者分析

第7章 頭孢克松市場 - 依適應症

  • 概述
    • 依適應症分類的細分市場佔有率分析
    • 泌尿道感染
    • 腹腔內感染
    • 心內膜炎
    • 急性細菌性中耳炎
    • 腦膜炎
    • 肺炎
    • 其他

第8章 頭孢克松市場 - 依配銷通路

  • 概述
    • 依配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第9章 頭孢克松市場 - 依地理位置

  • 介紹
    • 依地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美頭孢克松主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（依適應症）
    • 北美市場規模和預測（依配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲頭孢克松主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模與預測（依適應症）
    • 歐洲市場規模和預測（依配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區頭孢克松主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模與預測（依適應症）
    • 亞太地區市場規模和預測（依配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲頭孢克松主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模與預測（依適應症）
    • 拉丁美洲市場規模和預測（依配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲頭孢克松主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（依適應症）
    • 中東和非洲市場規模及預測（依配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA其他地區

第10章 主要供應商分析-頭孢克松產業

  • 競爭儀表板
  • 公司簡介
    • Hikma Pharmaceuticals plc
    • Qilu Pharmaceutical Co. Ltd.
    • Novartis AG
    • Baxter International, Inc.
    • Aurobindo Pharma
    • ACS DOBFAR SPA
    • Orchid Pharma
    • Nectar Lifesciences Ltd.
    • Lupin Pharmaceuticals
    • Others

第11章 360 度分析師視角

第12章 附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4060

REPORT HIGHLIGHT

Ceftriaxone Market size was valued at USD 2,010.32 Million in 2023, expanding at a CAGR of 3.29% from 2024 to 2032.

Ceftriaxone is a broad-spectrum cephalosporin antibiotic utilized for treating various bacterial infections. It functions by inhibiting the synthesis of bacterial cell walls, effectively killing or stunting the growth of susceptible bacteria. This antibiotic is commonly advised for conditions such as meningitis, pneumonia, and infections of the skin, urinary tract, and abdomen. Ceftriaxone can be administered intravenously or intramuscularly, ensuring a rapid absorption and effectiveness. Its long half-life allows for once-daily dosing in many instances, making it a convenient option for both hospital and outpatient settings. Ceftriaxone is recognized for its efficacy against diverse range of pathogens, establishing it as a cornerstone of an empirical antibiotic therapy. As a cephalosporin beta-lactam antibiotic, it targets bacterial infections caused by typically susceptible gram-positive organisms. In vitro studies have demonstrated that ceftriaxone is effective against gram-positive, gram-negative, and anaerobic bacteria. Its bactericidal action is attributed to its inhibition of cell wall synthesis, which occurs through binding to penicillin-binding proteins (PBPs).

Ceftriaxone Market- Market Dynamics

Increasing awareness among the public, and the rising geriatric population that is more susceptible to bacterial diseases to propel market demand

Ceftriaxone is administered via intravenous or intramuscular injection. When taken orally, its bioavailability is less than 1%. It is primarily used to treat urinary tract infections, intra-abdominal infections, endocarditis, acute bacterial otitis media, meningitis, and pneumonia. Additionally, ceftriaxone serves as the first-line treatment for neurosyphilis in patients who are allergic to penicillin. The injection is also given prior to certain surgeries to prevent post-operative infections. Common side effects of ceftriaxone include pain, hardness, tenderness, pale skin, diarrhea, weakness, and shortness of breath during exercise. However, it is important to note that ceftriaxone is ineffective against viral infections such as colds and the flu. The medication is available only with a doctor's prescription. The global ceftriaxone market is expected to grow in the near future due to the increasing incidence of urinary tract infections (UTIs), heightened awareness among the public, and the rising geriatric population that is more susceptible to bacterial diseases. The prevalence of major chronic diseases worldwide is anticipated to rise significantly in the coming years. The demand for ceftriaxone injections is being driven by the growing occurrence of UTIs, acute bacterial otitis media, intra-abdominal infections, and other bacterial conditions. UTIs, often caused by bacteria entering the bladder, are particularly common among women, with more than half likely to experience at least one UTI in their lifetime. These infections can be painful and pose serious health risks. The increasing use of ceftriaxone for treating UTIs is projected to contribute to the expansion of the ceftriaxone market. According to the National Center for Biotechnology Information, approximately 80% of children are expected to experience at least one episode of otitis media during their lifetime, with 80% to 90% likely to have otitis media with effusion before reaching school age. Moreover, the rising geriatric population, particularly in developed countries, is likely to increase the demand for ceftriaxone injections, as bacterial infections are more prevalent among individuals over the age of 65.

Ceftriaxone Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.29% over the forecast period (2024-2032)

Based on Indication segmentation, pneumonia was predicted to show maximum market share in the year 2023

Based on Distribution Channel segmentation, hospital pharmacies was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Ceftriaxone Market- Segmentation Analysis:

The Global Ceftriaxone Market is segmented on the basis of Indication, Distribution Channel, and Region.

The market is divided into seven categories based on Indication: Urinary Tract Infections, Intra-abdominal Infections, Endocarditis, Acute Bacterial Otitis Media, Meningitis, Pneumonia and Others. In the ceftriaxone market, pneumonia is the leading indication, driven by the rising prevalence of both community-acquired and hospital-acquired pneumonia, particularly among vulnerable groups such as the elderly and immunocompromised patients. Ceftriaxone's broad-spectrum efficacy against a wide range of pathogens positions it as a first-line treatment, frequently administered in hospital settings for its effectiveness in managing severe cases. While other indications, such as urinary tract infections and meningitis, are also notable, the high incidence of pneumonia and the urgent need for effective treatment solidify its status as the primary indication for ceftriaxone.

The market is divided into three categories based on Distribution Channel: Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. In the distribution channel segment, hospital pharmacies are the dominant in the ceftriaxone market. This predominance is primarily due to drug's primary use in inpatient settings for treating serious infections that necessitate immediate medical attention. Hospital pharmacies are essential for ensuring timely access to ceftriaxone for patients requiring critical care. Although retail and online pharmacies are significant for outpatient management, the urgent demand for ceftriaxone in hospital environments drives the majority of its sales through hospital pharmacies, highlighting the critical nature of the infections it addresses.

Ceftriaxone Market- Geographical Insights

This market covers North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa. Participating nations within these regions create sub-segments within the market. In 2023, North America held the largest share of the ceftriaxone market, positioning itself as a highly lucrative region for growth during the forecast period. This dominance can be attributed to the rising incidence of bacterial infections. Furthermore, the region benefits from a high adoption rate of technologically advanced products, significant healthcare expenditure, early access to innovative technologies, and favorable funding from governments and charitable organizations for healthcare research. These factors are expected to drive the expansion of the ceftriaxone market in the coming years. The U.S. emerged as the leader within North America, largely due to the presence of key industry players.

Ceftriaxone Market- Competitive Landscape:

Companies in the ceftriaxone market implement a variety of strategies to remain competitive and foster growth. Ongoing research and development efforts are dedicated to improving formulations, such as creating extended-release versions or combination therapies aimed at resistant strains. Strategic alliances with healthcare providers and institutions facilitate clinical trials and broaden the drug's application in various medical environments. Marketing initiatives emphasize the drug's efficacy, safety profile, and versatility in treating common infections, targeting both prescribers and hospitals. Furthermore, companies often participate in educational campaigns to raise awareness about the appropriate use of antibiotics, promoting ceftriaxone as a first-line treatment while addressing concerns regarding antibiotic resistance.

Recent Developments:

In September 2021, the Government of India implemented an anti-dumping duty on ceftriaxone raw materials imported from China to safeguard domestic manufacturers from low-cost imports.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CEFTRIAXONE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Hikma Pharmaceuticals plc
  • Qilu Pharmaceutical Co. Ltd.
  • Novartis AG
  • Baxter International, Inc.
  • Aurobindo Pharma
  • ACS DOBFAR S.P.A.
  • Orchid Pharma
  • Nectar Lifesciences Ltd.
  • Lupin Pharmaceuticals
  • Others

GLOBAL CEFTRIAXONE MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Urinary Tract Infections
  • Intra-abdominal Infections
  • Endocarditis
  • Acute Bacterial Otitis Media
  • Meningitis
  • Pneumonia
  • Others

GLOBAL CEFTRIAXONE MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL CEFTRIAXONE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Ceftriaxone Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Ceftriaxone Market Snippet by Indication
    • 2.1.2. Ceftriaxone Market Snippet by Distribution Channel
    • 2.1.3. Ceftriaxone Market Snippet by Country
    • 2.1.4. Ceftriaxone Market Snippet by Region
  • 2.2. Competitive Insights

3. Ceftriaxone Key Market Trends

  • 3.1. Ceftriaxone Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Ceftriaxone Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Ceftriaxone Market Opportunities
  • 3.4. Ceftriaxone Market Future Trends

4. Ceftriaxone Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Ceftriaxone Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Ceftriaxone Market Landscape

  • 6.1. Ceftriaxone Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Ceftriaxone Market - By Indication

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 7.1.2. Urinary Tract Infections
    • 7.1.3. Intra-abdominal Infections
    • 7.1.4. Endocarditis
    • 7.1.5. Acute Bacterial Otitis Media
    • 7.1.6. Meningitis
    • 7.1.7. Pneumonia
    • 7.1.8. Others

8. Ceftriaxone Market - By Distribution Channel

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 8.1.2. Hospital Pharmacies
    • 8.1.3. Retail Pharmacies
    • 8.1.4. Online Pharmacies

9. Ceftriaxone Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Ceftriaxone Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Ceftriaxone Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Ceftriaxone Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Ceftriaxone Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Ceftriaxone Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Ceftriaxone Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Hikma Pharmaceuticals plc
    • 10.2.2. Qilu Pharmaceutical Co. Ltd.
    • 10.2.3. Novartis AG
    • 10.2.4. Baxter International, Inc.
    • 10.2.5. Aurobindo Pharma
    • 10.2.6. ACS DOBFAR S.P.A.
    • 10.2.7. Orchid Pharma
    • 10.2.8. Nectar Lifesciences Ltd.
    • 10.2.9. Lupin Pharmaceuticals
    • 10.2.10. Others

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us